XRD pattern for the prepared titanium oxide nanofibers. by Nasser A. M. Barakat (11705885)

Subjects:

Plasticity limit (%) of pristine and modified Egyptian kaolin. by Nasser A. M. Barakat (11705885)

Subjects:

Chemical composition (%) of the Egyptian clay [9]. by Nasser A. M. Barakat (11705885)

Subjects:

Compression strength of pristine and modified Egyptian kaolin sintered at two temperatures: 900 and 1050 °C. by Nasser A. M. Barakat (11705885)

Subjects:

Apparent density of pristine and modified Egyptian kaolin sintered at two temperatures: 900 and 1050 °C. by Nasser A. M. Barakat (11705885)

Subjects:

Water absorption of pristine and modified Egyptian kaolin sintered at two temperatures: 900 and 1050 °C. by Nasser A. M. Barakat (11705885)

Subjects:

Percentage change in the apparent density of pristine and modified Egyptian kaolin sintered at 1050 °C for 4 successive cycles. by Nasser A. M. Barakat (11705885)

Subjects:

Porosity of pristine and modified Egyptian kaolin sintered at two temperatures: 900 and 1050 °C. by Nasser A. M. Barakat (11705885)

Subjects:

XRD pattern for the prepared silicon oxide nanoparticles. by Nasser A. M. Barakat (11705885)

Subjects:

Summary of nanostructured additives used in this study, including type, morphology, dimensions, and source or preparation method. by Nasser A. M. Barakat (11705885)

Subjects:

SEM images showing the microstructure of pristine kaolin. by Nasser A. M. Barakat (11705885)

Subjects:

Thermal gravimetric analyses and the first derivative for the obtained data for the CNTs; (A and B), AC; (C and D) and SiO₂; (E and F) compared with the pristine kaolin. by Nasser A. M. Barakat (11705885)

Subjects:

Effect of each additive on Kaolin ceramic properties at different sintering temperatures. by Nasser A. M. Barakat (11705885)

Subjects:

Table 1_Dexmedetomidine decreases cerebral hyperperfusion syndrome incidence following mechanical thrombectomy in acute ischemic stroke: a double-blind, randomized controlled trial... by Ziwen Gao (11627802)

Table 2_Dexmedetomidine decreases cerebral hyperperfusion syndrome incidence following mechanical thrombectomy in acute ischemic stroke: a double-blind, randomized controlled trial... by Ziwen Gao (11627802)

Table 3_Dexmedetomidine decreases cerebral hyperperfusion syndrome incidence following mechanical thrombectomy in acute ischemic stroke: a double-blind, randomized controlled trial... by Ziwen Gao (11627802)

Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P_i‐induced VSMCs. …”

Additional file 3 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Effect of <i>slc43a3</i> deletion on resting blood pressure (systolic and diastolic) and heart rate of male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Phase analysis data and within group correlations. by Aaron L. Sayler (19797446)

Subjects: